Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9
Crossref DOI link: https://doi.org/10.1007/s10549-015-3466-4
Published Online: 2015-07-01
Published Print: 2015-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Abraham, Jame
Robidoux, André
Tan, Antoinette R.
Limentani, Steven
Sturtz, Keren
Shalaby, Ibrahim
Alcorn, Hope
Buyse, Marc E.
Wolmark, Norman
Jacobs, Samuel A.
Funding for this research was provided by:
Eisai Inc.
Text and Data Mining valid from 2015-07-01